In 2025, in partnership with leading patient advocacy organizations, this grant mechanism will focus on furthering the understanding of the development, prevention, and therapy of resistance by supporting projects that seek to identify, characterize, treat or prevent resistance to lung cancer therapies. Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer (including lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer) and across the care continuum including newly designed targeted therapies and immunotherapies. These studies will enhance the momentum of improving lung cancer outcomes and have the potential to increase survivorship.
We encourage applications on a wide variety of topics related to understanding and/or overcoming resistance including but not limited to:
- Mechanisms of resistance to targeted therapies for oncogene-driven lung cancers. Proposals are encouraged in the areas of histological transformation, oligometastatic disease, oligo-remnant disease, uncommon mutations and non-genomic mechanisms of resistance.
- Biology and mechanisms of drug resistance to lung cancer therapies including chemotherapy, immunotherapy, radiotherapy, and antibody drug conjugates.
- Novel treatment approaches and new therapies to overcome and/or prevent resistance to lung cancer therapies.
- Novel diagnostic approaches (i.e. biomarkers) to monitor treatment response and relapse.
- Overcoming resistance in difficult to treat sites of metastases such as leptomeningeal and brain metastases.
Eligibility Criteria
Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment. Applicants from US-based and international institutions are eligible to apply and may hold any residency/citizenship status.
Applicants are prohibited from applying if they have received funding from the LCRF within the last 4 years and from applying in more than one of LCRF’s funding tracks in the same cycle.
Application
All applications for funding must be submitted online at Proposal Central through a two-stage process consisting of a letter of intent (LOI) and full proposal. Upon submission and review of the LOI, applicants whose submission is reviewed favorably will be invited to complete a full proposal.
Any applications for an extension of a previously awarded grant require resubmission as a new complete application (LOI and subsequent full proposal) and must include an update describing the progress made during the prior award period.
Deadline: 3 March 2025.
Español
English